BioLineRx Ltd. (BLRX)

Market Cap	46.12M
Revenue (ttm)	11.66M
Net Income (ttm)	-49.15M
Shares Out	86.69M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	393,903
Open	0.560
Previous Close	0.560
Day's Range	0.523 - 0.575
52-Week Range	0.523 - 2.530
Beta	0.93
Analysts	Strong Buy
Price Target	21.00 (+3,854.8%)
Earnings Date	May 28, 2024

About BLRX

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of ski...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX

Analyst Forecast

According to one analyst, the rating for BLRX stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target

$21.0

(3,854.80% upside)

Analyst Consensus: Strong Buy